A novel crizotinib-resistant solvent-front mutation responsive to cabozantinib therapy in a patient with ROS1-rearranged lung cancer.
Please update your blog. This is first time cabo has been shown to work in patient with criz-resistance.
Thanks for the link. While we have evidence that cabo is effective for some ROS1 patients, apparently it’s very toxic with severe side effects, so it’s not a first-choice therapy for ROS1.
hello.Im japanese,contact you at first time.
my mother (59 years old, never smoked a cigaret) was diagnosed with lungcancer in april 2015, EGFR and ALK-negative.
So continued normal chemo.
Ros1+ was found in March 2016,and started ros1 clinical trial DS-6051b(Phase 1)from September 2016. but,it was not good result…
but ros1 Inhibitory is still our hope.
We want to join to search our hope and exchange information.
Fill in your details below or click an icon to log in:
You are commenting using your WordPress.com account. ( Log Out / Change )
You are commenting using your Twitter account. ( Log Out / Change )
You are commenting using your Facebook account. ( Log Out / Change )
You are commenting using your Google+ account. ( Log Out / Change )
Connecting to %s
Notify me of new comments via email.